Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)-Reference-Cited by-同舟云学术

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

Published:2020-08-03 Issue:12 Volume:27 Page:1350-1356
ISSN:1530-0374
Container-title:Menopause
language:en
Short-container-title:

Author:

Santoro Nanette,Waldbaum Arthur,Lederman Samuel,Kroll Robin,Fraser Graeme L.,Lademacher Christopher,Skillern Laurence,Young James,Ramael Steven

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Earth and Planetary Sciences,General Environmental Science,Obstetrics and Gynecology

Reference31 articles.

1. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation;Gold;Am J Public Health,2006

2. Risk of long-term hot flashes after natural menopause: evidence from the Penn ovarian aging study cohort;Freeman;Menopause,2014

3. Healthcare seeking and treatment for menopausal symptoms in the United States;Williams;Maturitas,2007

4. Duration of menopausal vasomotor symptoms over the menopause transition;Avis;JAMA Intern Med,2015

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic routes and clinical application of new drugs approved by EMA during 2023;European Journal of Medicinal Chemistry;2024-11

2. Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-11

3. Menopause transition and cardiovascular disease risk;Maturitas;2024-07

4. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-06

5. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2);Menopause;2024-04-16